Display options
Cite
Rezania S, Amirmozaffari N, Rashidi N, et al. The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer Cell Int. 2014;14:54doi: 10.1186/1475-2867-14-54.
Rezania, S., Amirmozaffari, N., Rashidi, N., Mirzadegan, E., Zarei, S., Ghasemi, J., Zarei, O., Katouzian, L., & Zarnani, A. H. (2014). The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer cell international, 1454. https://doi.org/10.1186/1475-2867-14-54
Rezania, Simin, et al. "The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation." Cancer cell international vol. 14 (2014): 54. doi: https://doi.org/10.1186/1475-2867-14-54
Rezania S, Amirmozaffari N, Rashidi N, Mirzadegan E, Zarei S, Ghasemi J, Zarei O, Katouzian L, Zarnani AH. The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer Cell Int. 2014 Jun 19;14:54. doi: 10.1186/1475-2867-14-54. eCollection 2014. PMID: 24966802; PMCID: PMC4069277.
Copy Download .nbib Format: NLM
Share it on

Cancer Cell Int. 2014 Jun 19;14:54. doi: 10.1186/1475-2867-14-54. eCollection 2014.

The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation.

Cancer cell international

Simin Rezania, Noor Amirmozaffari, Nesa Rashidi, Ebrahim Mirzadegan, Saeed Zarei, Jamileh Ghasemi, Omid Zarei, Leila Katouzian, Amir-Hassan Zarnani

Affiliations

  1. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran ; Biophysics Institute, Medical University of Graz, Graz, Austria.
  2. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  3. Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
  4. Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
  5. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
  6. Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
  7. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  8. Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran ; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.

PMID: 24966802 PMCID: PMC4069277 DOI: 10.1186/1475-2867-14-54

Abstract

BACKGROUND: Many types of tumors are organized in a hierarchy of heterogeneous cell populations with different molecular signature. Such heterogeneity may be associated with different responsiveness to microenvironment stimuli. In the present study, the effects of lipopolysaccharide (LPS) and lipoteichoic acid (LTA), as well-known mediators of inflammation, on cancerous behavior of three prostate tumor cells, LNCaP, PC3 and DU145, were investigated.

METHODS: Expression of TLR1-10, CD14 and MyD88 transcripts was investigated by RT-PCR. Protein expression of TLR2 and 4 was scrutinized by flow cytometry, immunofluorescent staining and Western blotting. Experiments were set up to assess the effects of LPS and LTA at different concentrations and times on cell proliferation, extracellular matrix invasion, adhesion and cytokine production.

RESULTS: We showed that prostate cancer cell lines differentially express TLR1-10, MyD88 and CD14 transcripts. DU145 failed to express TLR4 gene. Positively-identified TLR2 protein in all prostate cancer cells and TLR4 protein in PC3 and LNCaP by Western blotting was not accompanied by cell surface expression, as judged by flow cytometry. Immunofluorescent staining clearly demonstrated predominantly perinuclear localization of TLR2 and TLR4. LTA activation of all prostate cancer cells significantly increased cell proliferation. Regardless of lacking TLR4, DU145 cells proliferated in response to LPS treatment. While LPS caused increased invasiveness of LNCaP, invasive capacity of PC3 was significantly reduced after LPS or LTA stimulation. Stimulation of all prostate tumor cells with LTA was associated with increased cell adhesion and IL-8 production. IL-6 production, however, was differentially regulated by LPS stimulation in prostate tumor cells.

CONCLUSION: The data shows that cancer cells originated from the same histologically origin exhibit heterogeneous response to the same TLR ligand. Therefore, a thorough and comprehensive judgment on how and to what extent a particular cancer is affected by TLR agonist could not be inferred by studying an individual cell line.

Keywords: Adhesion; Inflammation; Invasion; Pro-inflammatory cytokine; Proliferation; Prostate cancer; Toll like receptor

References

  1. Br J Cancer. 1999 Dec;81(8):1311-7 - PubMed
  2. Immunology. 2000 Sep;101(1):1-10 - PubMed
  3. Int J Cancer. 2002 Oct 10;101(5):415-22 - PubMed
  4. Int Immunol. 2001 Dec;13(12):1595-9 - PubMed
  5. Nat Rev Cancer. 2007 Apr;7(4):256-69 - PubMed
  6. Br J Cancer. 2000 Feb;82(3):718-25 - PubMed
  7. Urol Oncol. 2013 Oct;31(7):951-65 - PubMed
  8. J Biol Chem. 1998 May 15;273(20):12203-9 - PubMed
  9. Physiol Rev. 2003 Apr;83(2):337-76 - PubMed
  10. J Biol Chem. 2002 Mar 8;277(10):7808-15 - PubMed
  11. Am J Reprod Immunol. 2004 Jul;52(1):67-73 - PubMed
  12. Oncogene. 2008 Jan 7;27(2):225-33 - PubMed
  13. Cancer Res. 2005 Jun 15;65(12):5009-14 - PubMed
  14. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):588-93 - PubMed
  15. J Exp Med. 2003 Oct 20;198(8):1225-35 - PubMed
  16. Nature. 2000 Dec 7;408(6813):740-5 - PubMed
  17. Cancer Res. 1999 Mar 15;59(6):1225-30 - PubMed
  18. Vaccine. 2003 Jun 1;21 Suppl 2:S55-60 - PubMed
  19. Clin Cancer Res. 2013 Mar 15;19(6):1340-6 - PubMed
  20. Curr Opin Urol. 2008 May;18(3):315-9 - PubMed
  21. Nat Rev Cancer. 2009 Jan;9(1):57-63 - PubMed
  22. J Biol Chem. 2004 Mar 26;279(13):12542-50 - PubMed
  23. FASEB J. 2004 Jul;18(10):1117-9 - PubMed
  24. Curr Urol Rep. 2008 May;9(3):243-9 - PubMed
  25. Cancer Res. 2006 Apr 1;66(7):3859-68 - PubMed
  26. Nat Rev Immunol. 2009 Aug;9(8):535-42 - PubMed
  27. Prostate. 1997 Jan 1;30(1):58-64 - PubMed
  28. Cancer Gene Ther. 2006 Jan 1;13(1):21-31 - PubMed
  29. Placenta. 2011 Sep;32(9):657-664 - PubMed
  30. Nature. 2001 Oct 18;413(6857):732-8 - PubMed
  31. Nature. 2001 Apr 26;410(6832):1099-103 - PubMed
  32. J Reprod Immunol. 2009 Jun;80(1-2):41-8 - PubMed
  33. Nature. 1998 Sep 17;395(6699):284-8 - PubMed
  34. Prostate. 2006 Mar 1;66(4):386-91 - PubMed
  35. Immunol Rev. 2000 Feb;173:89-97 - PubMed
  36. Cancer Res. 2000 Jul 1;60(13):3429-34 - PubMed
  37. Cancer Immunol Immunother. 2009 Sep;58(9):1375-85 - PubMed
  38. Nature. 2007 Apr 5;446(7136):690-4 - PubMed
  39. Carcinogenesis. 2009 Jul;30(7):1073-81 - PubMed
  40. Immunity. 1997 Dec;7(6):837-47 - PubMed
  41. Microbes Infect. 2004 Dec;6(15):1382-7 - PubMed
  42. J Immunol. 2010 Jun 15;184(12):6658-69 - PubMed
  43. J Biol Chem. 2005 Oct 28;280(43):36529-40 - PubMed
  44. J Immunol. 2003 Jan 15;170(2):795-804 - PubMed
  45. Nat Immunol. 2002 Jun;3(6):499 - PubMed
  46. Fertil Steril. 2013 Sep;100(3):761-9 - PubMed
  47. J Biol Chem. 1999 Jun 18;274(25):17406-9 - PubMed
  48. BMC Cancer. 2006 Dec 08;6:281 - PubMed
  49. J Biol Chem. 2004 Sep 24;279(39):40882-9 - PubMed
  50. Cancer Lett. 2009 Apr 8;276(1):38-46 - PubMed
  51. Lancet. 2001 Feb 17;357(9255):539-45 - PubMed
  52. N Engl J Med. 2003 Jul 24;349(4):366-81 - PubMed
  53. Cancer Res. 2007 May 1;67(9):4346-52 - PubMed
  54. Nat Rev Cancer. 2004 Jul;4(7):519-27 - PubMed
  55. Epidemiology. 2002 Jan;13(1):72-9 - PubMed
  56. Cancer Lett. 2006 Apr 8;235(1):75-83 - PubMed
  57. Nature. 2002 Dec 19-26;420(6917):860-7 - PubMed
  58. Nat Rev Immunol. 2010 Aug;10(8):580-93 - PubMed
  59. Biochem Biophys Res Commun. 2009 Feb 20;379(4):1027-32 - PubMed
  60. Respir Res. 2005 Jan 04;6:1 - PubMed
  61. J Immunol. 2003 Oct 15;171(8):4304-10 - PubMed
  62. J Biol Chem. 2003 Jun 27;278(26):23432-40 - PubMed
  63. Science. 1997 Nov 28;278(5343):1612-5 - PubMed
  64. Nat Immunol. 2002 Jul;3(7):667-72 - PubMed
  65. Oncogene. 2004 Jan 22;23(3):706-15 - PubMed
  66. Nature. 2010 Mar 11;464(7286):302-5 - PubMed
  67. J Reprod Immunol. 2008 Jan;77(1):7-13 - PubMed
  68. Int J Med Microbiol. 2005 Jun;295(3):179-85 - PubMed
  69. J Proteome Res. 2008 Aug;7(8):3329-38 - PubMed
  70. Nature. 1997 Jul 24;388(6640):394-7 - PubMed
  71. Eur Arch Otorhinolaryngol. 2007 May;264(5):525-30 - PubMed
  72. Mol Carcinog. 2007 Nov;46(11):941-7 - PubMed
  73. Prostate. 2007 May 15;67(7):774-81 - PubMed
  74. J Endotoxin Res. 2000;6(5):401-5 - PubMed
  75. Oncogene. 2008 Jan 7;27(2):218-24 - PubMed
  76. Br J Urol. 1998 May;81(5):730-4 - PubMed
  77. Prostate. 2009 Jul 1;69(10):1077-90 - PubMed
  78. J Cell Mol Med. 2013 Jun;17(6):713-22 - PubMed
  79. J Biol Chem. 2004 Feb 13;279(7):5405-12 - PubMed

Publication Types